Patient-tailored therapy in rheumatoid arthritis: An editorial review

Current Opinion in Rheumatology

Volumn 22, Issue 3, 2010, Pages 237-245

  Scherer, Hans U ^a   Dörner, Thomas ^a   Burmester, Gerd R ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Biologic therapy; Methotrexate; Patient tailored therapy; Personalized medicine; Rheumatoid arthritis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ADALIMUMAB; ADENOSINE MONOPHOSPHATE DEAMINASE; ARYLDIALKYLPHOSPHATASE 1; BIOLOGICAL MARKER; BIOMATERIAL; C REACTIVE PROTEIN; CD27 ANTIGEN; CERTOLIZUMAB PEGOL; ETANERCEPT; GAMMA GLUTAMYL HYDROLASE; GOLIMUMAB; IMMUNOGLOBULIN D; INFLIXIMAB; INOSINE TRIPHOSPHATE PYROPHOSPHATASE; INTERLEUKIN 1; INTERLEUKIN 6; LEFLUNOMIDE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; PHOSPHORIBOSYLAMINOIMIDAZOLECARBOXAMIDE FORMYLTRANSFERASE; REDUCED FOLATE CARRIER 1; RITUXIMAB; SERINE HYDROXYMETHYLTRANSFERASE 1; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

CLINICAL DECISION MAKING; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GENE EXPRESSION; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEOMICS; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOMARKERS, PHARMACOLOGICAL; CLINICAL PROTOCOLS; DRUG DESIGN; HUMANS; IMMUNOLOGIC FACTORS; METHOTREXATE; PHYSICIAN-PATIENT RELATIONS; RHEUMATIC DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77950190617     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328337b832     Document Type: Review

References (93)

1. Obama B. S. 976-The Genomics And Personalized Medicine Act of 2007. http://olpa.od.nih.gov/tracking/110/senate-bills/session1/s-976.asp.
2. Center for Personalized Genetic Medicine. http://www.hpcgg.org/.
3. Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 1998; 52:65-77.
4. Modjtahedi H, Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs 2009; 20:851-855.
5. Oake N, Fergusson DA, Forster AJ, van Walraven C. Frequency of adverse events in patients with poor anticoagulation: a meta-analysis. CMAJ 2007; 176:1589-1594.
6. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358:999-1008.
7. Shuldiner AR, O'Connell JR, Bliden KP, etal. Associationofcytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302:849-857.
8. Salari K. The dawning era of personalized medicine exposes a gap in medical education. PLoS Med 2009; 6:e1000138.
9. Verweij CL. Predicting the future of antitumor necrosis factor therapy. Arthritis Res Ther 2009; 11:115.
10. Bridges SL Jr. Personalized medicine in rheumatoid arthritis: hopes and challenges. Bull NYU Hosp Jt Dis 2007; 65:174-177.
11. Nell VP, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying antirheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004; 43:906-914.
12. van Dongen H,van Aken J, Lard LR, etal. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007; 56:1424-1432.
13. van der Helm-van Mil AH, le Cessie S, van Dongen H, et al. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum 2007; 56:433-440.
14. Mjaavatten MD, Uhlig T, Haugen AJ, et al. Positive anticitrullinated protein antibody status and small joint arthritis are consistent predictors of chronic disease in patients with very early arthritis: results from the NOR-VEAC cohort. Arthritis Res Ther 2009; 11:R146.
15. van der Helm-van Mil AH, Detert J, le Cessie S, et al. Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making. Arthritis Rheum 2008; 58:2241-2247.
16. Bukhari M, Thomson W, Naseem H, et al. The performance of anticyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: results from the Norfolk Arthritis Register. Arthritis Rheum 2007; 56:2929-2935.
17. Wagner E, Ammer K, Kolarz G, et al. Predicting factors for severity of rheumatoid arthritis: a prospective multicenter cohort study of 172 patients over 3 years. Rheumatol Int 2007; 27:1041-1048.
18. van der Linden MP, Feitsma AL, le Cessie S, et al. Association of a single-nucleotide polymorphism in CD40 with the rate of joint destruction in rheumatoid arthritis. Arthritis Rheum 2009; 60:2242-2247.
19. Scherer HU,van der Linden MP, Kurreeman FA, et al. Association of the 6q23 region with the rate of joint destruction in rheumatoid arthritis. Ann Rheum Dis 2009. doi:10.1136/ard.2008.106161.
20. Hoppe B, HauplT, EgererK, etal. Influence of peptidylargininedeiminase type 4 genotype and shared epitope on clinical characteristics and autoantibody profile of rheumatoid arthritis. Ann Rheum Dis 2009; 68:898-903.
21. HiderSL, SilmanAJ, Thomson W, etal. Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis? Ann Rheum Dis 2009; 68:57-62.
22. Drozdzik M, Rudas T, Pawlik A, et al. Reduced folate carrier-1 80GA polymorphism affects methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics J 2007; 7:404-407.
23. Hayashi H, Fujimaki C, Daimon T, et al. Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis. J Clin Pharm Ther 2009; 34:355-361.
24. Wessels JA, Vries-Bouwstra JK, Heijmans BT, et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleo-tide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum 2006; 54:1087-1095.
25. Dervieux T, Furst D, Lein DO, et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxa-mide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004; 50:2766-2774.
26. Sharma S, Das M, Kumar A, et al. Purine biosynthetic pathway genes and methotrexate response in rheumatoid arthritis patients among north Indians. Pharmacogenet Genomics 2009; 19:823-828.
27. Rego-Perez I, Fernandez-Moreno M, Blanco FJ. Gene polymorphisms and pharmacogenetics in rheumatoid arthritis. Curr Genomics 2008; 9:381-393.
28. Braun J, Rau R. An update on methotrexate. Curr Opin Rheumatol 2009; 21:216-223.
29. Ranganathan P, McLeod HL. Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum 2006; 54:1366-1377.
30. Hughes LB, Beasley TM, Patel H, et al. Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydro-folate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann Rheum Dis 2006; 65:1213-1218.
31. Dervieux T. Pharmacogenomics of methotrexate in rheumatoid arthritis: does race make a difference? J Rheumatol 2008; 35:550-552.
32. Ranganathan P, Culverhouse R, Marsh S, etal. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol 2008; 35:572-579.
33. Bohanec GP, Logar D, Lestan B, Dolzan V. Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. Eur J Clin Pharmacol 2008; 64:1057-1068.
34. Taraborelli M, Andreoli L, Archetti S, etal. Methylenetetrahydrofolate reductase polymorphisms and methotrexate: no association with response to therapy nor with drug-related adverse events in an Italian population of rheumatic patients. Clin Exp Rheumatol 2009; 27:499-502.
35. Dervieux T, Wessels JA, van der ST et al. Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis. Pharmacogenet Genomics 2009. doi:10.1097/ FPC.0b013e32833315d1.
36. Wessels JA, van der Kooij SM, le Cessie S, etal. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum 2007; 56:1765-1775.
37. Kooloos WM, Wessels JA, van der Kooij SM, et al. Optimalization of the clinical pharmacogenetic model to predict methotrexate treatment response: the influence of the number of haplotypes of MTHFR 1298A-677C alleles on probability to respond. Ann Rheum Dis 2009; 68:1371. Plenge RM, Cotsapas C, Davies L, et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet 2007;39:1477-1482.
38. Thomson W, Barton A, Ke X, etal. Rheumatoid arthritis association at 6q23. Nat Genet 2007; 39:1431-1433.
39. Kurreeman FAS, Padyukov L, Marques RB, etal. A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritis. Plos Med 2007; 4:e278.
40. Visser K, Verpoort KN, van Dongen H, et al. Pretreatment serum levels of anticyclic citrullinated peptide antibodies are associated with the response to methotrexate in recent-onset arthritis. Ann Rheum Dis 2008; 67:1194-1195.
41. Buch MH, Bingham SJ, Bejarano V, et al. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. Arthritis Rheum 2007; 57:448-453.
42. Cohen G, Courvoisier N, Cohen JD, et al. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005; 23:795-800.
43. Hyrich KL, Lunt M, Watson KD, et al. Outcomes after switching from one antitumor necrosis factor alpha agent to a second antitumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007; 56:13-20.
44. Kang CP, Lee KW, YooDH, et al. The influence of a polymorphism at position-857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxford) 2005; 44:547-552.
45. Schotte H, Schluter B, Drynda S, etal. Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64:575-581.
46. Criswell LA, Lum RF, Turner KN, et al. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum 2004; 50:2750-2756.
47. Padyukov L, Lampa J, Heimburger M, etal. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 2003; 62:526-529.
48. Mugnier B, Balandraud N, Darque A, et al. Polymorphism at position-308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003; 48:1849-1852.
49. Fonseca JE, Carvalho T, Cruz M, et al. Polymorphism at position-308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics. Ann Rheum Dis 2005; 64:793-794.
50. Cuchacovich M, Ferreira L, Aliste M, et al. Tumour necrosis factor-alpha (TNF-alpha) levels and influence of-308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis. Scand J Rheumatol 2004; 33:228-232.
51. Marotte H, Pallot-Prades B, Grange L, et al. The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population. Ann Rheum Dis 2006; 65:342-347.
52. Martinez A, Salido M, Bonilla G, et al. Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients. Arthritis Rheum 2004; 50:1077-1082.
53. Tolusso B, Pietrapertosa D, Morelli A, et al. IL-1B and IL-1RN gene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy. Pharmacogenomics 2006; 7:683-695.
54. Chatzikyriakidou A, Georgiou I, Voulgari PV, et al. Combined tumour necrosis factor-alpha and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients' response to anti-TNF-alpha therapy and explain controversies of studies based on a single polymorphism. Rheumatology (Oxford) 2007; 46:1034-1035.
55. Miceli-Richard C, Comets E, Verstuyft C, et al. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Ann Rheum Dis 2008; 67:478-484.
56. Cuchacovich M, Soto L, Edwardes M, et al. Tumour necrosis factor (TNF) alpha-308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. Scand J Rheumatol 2006; 35:435-440.
57. Fabris M, Tolusso B, Di Poi E, et al. Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis. J Rheumatol 2002; 29:1847-1850.
58. Kastbom A, Bratt J, Ernestam S, et al. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis. Arthritis Rheum 2007; 56:448-452.
59. Tutuncu Z, Kavanaugh A, Zvaifler N, et al. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum 2005; 52:2693-2696.
60. Liu C, Batliwalla F, Li W, et al. Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol Med 2008; 14:575-581.
61. Seitz M, Wirthmuller U, Moller B, Villiger PM. The-308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-block-ers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford) 2007; 46:93-96.
62. Bowes JD, Potter C, Gibbons LJ, et al. Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. Pharmaco-genet Genomics 2009; 19:319-323.
63. Potter C, Hyrich KL, Tracey A, et al. Association of rheumatoid factor and anticyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with antitumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis 2009; 68:69-74.
64. Plenge RM, Criswell LA. Genetic variants that predict response to antitumor necrosis factor therapy in rheumatoid arthritis: current challenges and future directions. Curr Opin Rheumatol 2008; 20:145-152.
65. Coenen MJ, Toonen EJ, Scheffer H, et al. Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis. Pharmacogenomics 2007; 8:761-773.
66. Marotte H, Arnaud B, Diasparra J, et al. Association between the level of circulating bioactive tumor necrosisfactoralpha and thetumor necrosis factoralpha gene polymorphism at-308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor. Arthritis Rheum 2008; 58:1 258-1263.
67. Pavy S, Toonen EJ, Miceli-Richard C, et al. TNF alpha-308 GA polymorph-ism is not associated with response to TNF-alpha-blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis 2009. doi:10.1136/ard.2009.117622.
68. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Antiadalimumab anti-bodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms. Arthritis Rheum 2009; 60:2541-2542.
69. CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis
70. Morozzi G, Fabbroni M, Bellisai F, et al. Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis. Clin Rheumatol, 2007. 26,1335-1338
71. Lequerre T, Gauthier-Jauneau AC, Bansard C, et al. Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res Ther 2006; 8:R105.
72. Lindberg J, afKlint E, Catrina AI, et al. Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients. Arthritis Res Ther 2006; 8:R179.
73. van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, et al. Responsiveness to antitumour necrosis factor alpha therapy is related to pretreatment tissue inflammation levels in rheumatoid arthritis patients. Ann Rheum Dis 2008; 67:563-566.
74. Klaasen R, Thurlings RM, Wijbrandts CA, et al. The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study. Arthritis Rheum 2009; 60:3217-3224.
75. Buch MH, Seto Y, Bingham SJ, et al. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept. Arthritis Rheum 2005; 52:42-48.
76. Braun-Moscovici Y, MarkovitsD,ZinderO, et al. Anticyclic citrullinated protein antibodies as a predictor of response to antitumor necrosis factor-alpha therapy in patients with rheumatoid arthritis. J Rheumatol 2006; 33: 497-500.
77. Koczan D, Drynda S, Hecker M, et al. Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept. Arthritis Res Ther 2008; 10:R50.
78. Hueber W, Tomooka BH, Batliwalla F, et al. Blood autoantibody and cytokine profiles predict response to antitumor necrosis factor therapy in rheumatoid arthritis. Arthritis Res Ther 2009; 11:R76.
79. Fabre S, Dupuy AM, Dossat N, et al. Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis. Clin Exp Immunol 2008; 153:188-195.
80. Hyrich KL, Watson KD, Silman AJ, Symmons DP. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006; 45:1558-1565.
81. Bobbio-Pallavicini F, Caporali R, Alpini C, et al. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis 2007; 66:302-307.
82. Lindberg J, af Klint E, Ulfgren AK, et al. Variability in synovial inflammation in rheumatoid arthritis investigated by microarray technology. Arthritis Res Ther 2006; 8:R47.
83. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to antitumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54:2793-2806.
84. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54:1390-1400.
85. Quartuccio L, Lombardi S, Fabris M, et al. Long-term effects of rituximab in rheumatoid arthritis: clinical, biologic, and pharmacogenetic aspects. Ann N Y Acad Sci 2009; 1173:692-700.
86. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fcgam-maRIIIa gene. Blood 2002; 99:754-758.
87. Anolik JH, Campbell D, Felgar RE, et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003; 48:455-459
88. Roll P, Dorner T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 2008; 58:1566-1575
89. Dass S, Rawstron AC, Vital EM, etal. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 2008; 58:2993-2999.
90. Quartuccio L, Fabris M, Salvin S, etal. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford) 2009; 48:1557-1559.
91. Tak PP, Rigby WFC, Rubbert-Roth A, etal. Rituximab in combination with methotrexate (MTX) significantly inhibits joint damage and improves clinical outcomes in patients with early active RA who are nave to MTX: a randomized active comparator placebo-controlled trial (IMAGE) [abstract]. Arthritis Rheum 2009; 60 (Suppl 10):636.
92. Fishman D, Faulds G, Jeffery R, etal. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102:1369-1376.
93. Littman BH. Tocilizumab and missed personalized medicine opportunities for patients with rheumatoid arthritis? Arthritis Rheum 2009; 60:1565-1566.